tbuckley/cabot-search huggingface dataset:
Abstract P4-02-03: Gene Copy Number Alterations Related to mRNA and miRNA Expression in Endocrine Resistant Breast Cancers
Authors: A Larionov, JS Reis-Filho, MBK Lambros, D Sproul, JM. Dixon
Journal: Cancer Research (2010)

Abstract Background Endocrine resistance is a major clinical issue in breast cancer. Multiple studies provide data relating molecular features of primary tumours on their response to endocrine treatment. However, there is a paucity of data on molecular profiles of breast tumours at time when endocrine resistance has already manifested. Aim Provide multilayer molecular profiling of a series of breast tumours at time of relapse or progression on endocrine treatment. Results High density microarray-comparative genomic hybridisation (aCGH) analysis was performed in 39 endocrine treated breast tumours at time of progression or relapse. 25 of these tumours were also profiled using whole genome mRNA and miRNA arrays (HT-12 mRNA array and DASL Sentrix Array Matrix micro-RNA array, Illumina). Overall the aCGH profiles of resistant tumours were similar to aCGH profiles of un-selected luminal breast tumours and cell lines published earlier. The most common gene copy gain areas (&amp;gt;10M of length) were located in 1q23.1-44, 5p13.1-33, 8p11.23-q24.3, 16p12.1-13.3, 17q21.33-24.1 and 20q13.2-13.33, while the most common losses were in 1p33-36.32, 8p12-23.3, 11q22.3-24.1, 16q12.2-24.3 and 17p11.2-13.3. Unsupervised hierarchical clustering by gene copy number profiles split of the resistant tumours into 3 groups. As expected, on average mRNAs and microRNAs were higher expressed in tumours carrying gains of their genes and were decreased in tumours carrying the losses. Copy number gains in this series were associated with the upregulation of multiple RNAs, including C8orf76, TATDN1, CYC1, ZBTB10, C16orf63, THUMPD1, TFB2M, miR-454, miR-301a and miR-296-3p/5p. Losses were associated with the downregulation of RNAs including ACADVL, BNIP3L, UBE4A, REXO2, ATP5L, PPP2CB, NBL1 and PCM1. Of the above genes UBE4A and ATP5L are closely co-localised in 11q23.3; miR454-miR301a are located closely in 17q22. Such associations suggest that changes in expression of these genes in breast cancers may be driven by alterations in the gene copy number. Analysis of the recurrent amplification regions on this dataset is underway. Conclusions aCGH profiles of endocrine resistant tumours at time of relapse or progression are similar to those found in un-selected and non-treated luminal tumours. The study provides the first dataset integrating gene copy number with mRNA and microRNA gene expressions in clinical specimens of endocrine resistant breast cancers. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-02-03.
Abstract P2-09-18: High VEGFR1 and VEGFR3 Protein Expression Is Associated with Improved Response to the Combination of Paclitaxel (P) and Bevacizumab (Bev) Therapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC)
Authors: C Papadimitriou, H Kourea, K Papazisis, C Christodoulou, E Res, P Papakostas, K Petraki, D Bafaloukos, E Razis, G. Fountzilas
Journal: Cancer Research (2010)

Abstract Background: Treatment with weekly P and 2-weekly Bev has been established as an active 1st line treatment in patients with MBC. However, robust predictive or prognostic biomarkers for this treatment have not been identified as yet. Patients and Methods: In this retrospective analysis, we evaluated the activity of this combination in patients with HER2-negative MBC. Further, we explored the role of a panel of biomarkers on patients’ outcome. VEGF-A, VEGF-C, VEGFR1, VEGFR2, and VEGFR3 were centrally assessed by immunohistochemistry (IHC) in 70 tissue blocks. P was administered either weekly 90 mg/m2 x12 with 2-weekly Bev 10 µg/kg (86 patients) or 3-weekly 175 mg/m2 x6 with 3-weekly Bev 15µg/kg (38 patients). Bev was administered until progression in the majority of the patients. Results: The ORR did not differ significantly between the weekly or 3-weekly P schedule (55.8% vs 55.3%). In contrast to the published literature with P monotherapy, median PFS was significantly longer in the 3-weekly compared to the weekly P schedule (20.4 months vs 10.2 months, p=0.029). Median survival has not been reached yet. 2-year survival was 76.1% and 67.3%, respectively (p=0.085). High VEGFR1 and VEGFR3 protein expression, assessed by IHC, was associated with higher response rates (p=0.010 and p=0.039, respectively). Conclusions: This retrospective analysis confirmed the activity of P and Bev in patients with HER2-negative MBC. Protein expression of VEGFR1 and VEGFR3 was found to be of predictive value. These findings need to be validated in a larger cohort of patients treated with this combination. VEGF polymorphisms (VEGF-2578 and VEGF-1154) are currently assessed in peripheral blood DNA from our patients for possible predictive value. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-18.
PTH-123 Quality Of Life And Performance Status Scores Following Intestinal Transplantation Are Similar To Those Of Patients On Home Parenteral Nutrition In The Uk: Abstract PTH-123 Table 1
Authors: C Pither, S Duncan, A Butler, M Stroud, T Smith, P Calder, G Rui, B Chukualim, J Woodward, J Green, R Charlotte, L Sharkey, S Gabe, S Middleton
Journal: Gut (2014)

<h3>Introduction</h3> Survival following Intestinal transplantation (ITX) has improved, approaching that of home parenteral nutrition (HPN) at 5 years. We describe quality of life (QOL) and performance status (PS) on uncomplicated HPN, those with criteria for ITX due to complicated HPN (CHPN) and those after ITX. <h3>Methods</h3> SF36 was used to assess QOL. Performance status was assessed by health related visual analogue scale (VAS), ECOG and Karnofsky performance score (KS). <h3>Results</h3> [Table – grouped data]. There was a trend for QOL and PS to be lower on CHPN than HPN and ITX (not significant, NS) Paired data for SF36 pretransplant (CHPN) and post-transplant revealed “general health “was the only function to significantly improve (p &lt; 0.05). Individual patients’ total scores improved in 4/11 with a statistically significant improvement in a further in 3/11(p &lt; 0.05) and were worse in 3/11. PS showed a trend for improvement post ITX compared to CHPN and HPN [All Wilcoxon signed rank, NS]. <h3>Conclusion</h3> SF36 improves significantly in approximately 25%, but falls in 25% after ITX compared CHPN and trends suggest performance improvement after ITX. With more data effects of ITX on QOL and PS will emerge and if improvements are confirmed earlier transplantation for those dependent on HPN may be justifiable. <h3>Disclosure of Interest</h3> None Declared.
Abstract 4854: Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion positive and fusion negative prostate cancer
Authors: Antje Krohn, Phillip Stahl, Lia Burkhardt, Clarissa Gerhäuser, Joseph Huang, Malte Mader, Hüseyin Sirma, Christoph Plass, Guido Sauter, Sarah Minner, Ronald Simon, Thorsten Schlomm
Journal: Cancer Research (2012)

Abstract The PTEN (Phospatase and Tensin Homolog deleted on chromosome Ten) gene is frequently altered in prostate cancer. To determine the prevalence and clinical significance of different mechanisms of PTEN inactivation, we analyzed 4,699 hormone-naïve and 57 hormone-refractory prostate cancers by fluorescence in situ hybridization for PTEN deletion. In addition, PTEN mutations and promoter methylation were analyzed in subsets of 149 and 34 tumors. PTEN deletions were present in 20.2% (458/2,266) of prostate cancers harboring and heterozygous (8.1%) and homozygous (12.1%) deletions. Deletions of PTEN were linked to advanced tumor stage (p&amp;lt;0.0001), high Gleason grade (p&amp;lt;0.0001), presence of lymph-node metastasis (p=0.0002), hormone refractory disease (p&amp;lt;0.0001), presence of ERG gene fusion (p&amp;lt;0.0001), and nuclear p53 accumulation (p&amp;lt;0.0001). PTEN deletions were also associated with early PSA recurrence in univariate (p&amp;lt;0.0001) and multivariate analysis (p=0.0158) if compared to the established risk factors pT stage, Gleason grade, and preoperative PSA level. The PTEN deletion had the identical prognostic impact in both in ERG fusion-positive and -negative tumors. PTEN mutations were found in 4 of 26 (15%) of cancers with heterozygous PTEN deletion, but in only 1 of 59 (2%) of cancers without PTEN deletion (p=0.0183). Analysis of the PTEN promoter for methylation changes in 34 tumors revealed no aberrations. The results of this study demonstrate that biallelic inactivation of PTEN, either by homozygous deletion or by deletion of one allele and mutation of the second one, occurs in the majority of prostate cancers with PTEN alteration and is characteristic feature for a particularly aggressive subset of metastatic and hormone-refractory prostate cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4854. doi:1538-7445.AM2012-4854
Case 8-2009
Authors: Aneesh B. Singhal, W. Taylor Kimberly, Pamela W. Schaefer, E. Tessa Hedley-Whyte
Journal: New England Journal of Medicine (2009)

Severe headaches associated with hypertension developed in a 36-year-old woman 10 days after delivery of twins by cesarean section; initial brain magnetic resonance imaging (MRI) and computed tomographic examinations were normal. Headaches persisted despite antihypertensive medications; a seizure and an episode of aphasia and hemiparesis occurred. Repeated MRI and magnetic resonance angiography showed posterior white-matter changes on T2-weighted sequences and multifocal narrowing and dilatation of intracranial arteries. A diagnostic procedure was performed.
AB0144 The expression of NKG2D ligands in synovial cell of rhuematoid arhtirits
Authors: S.Y. Lee, W.T. Chung, S.W. Lee, J.-H. Bae, C.W. Lee, E.J. Kang
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> NK cellare approximately 10–15% of circulating lymphocytes and 5% of lymphocytes in lymphoid tissue and a subset of NK cells has been detected in the synovial fluid (SF) from rheumatoid arthritis (RA) patients recently. The best characterised NK cell activating receptor is NKG2D, is expressed on all human NK cells and the ligands for NKG2D are not expressed on normal, healthy tissue, but are in induced under conditions of cellular stress such as inflammation and malignant transformation <h3>Objectives</h3> To investigated expression of NKG2D ligands in synovial cell of rhuematoid arhtirits <h3>Methods</h3> Synovial cell was cultured from SF of RA patients. The subculture was conducted for 5-6 passages and the PCR was done for detection of NKG2D ligands. To evaluated NKG2D ligands in inflammatory RA synoviocytes, TNF-α were treated <h3>Results</h3> Five NKG2D ligands (MICA, MICB, ULPB1, ULBP2, ULBP3) were expressed in both RA synoviocytes and inflammatory RA synoviocytes <h3>Conclusions</h3> RA synoviocytes had NKG2D ligands, so NKG2D receptors in NK cell were associated with pathogenesis of RA. The blocking of NKG2D ligands was the one of method in RA treatment <h3>References</h3> Emerging role for NK cells in the pathogenesis of inflammatory arthropathies, Paola Conigliaro, Rossana Scrivo, Guido Valesini, Roberto Perricone. Autoimmunity Reviews 10 (2011) 577–581 <h3>Disclosure of Interest</h3> None Declared
Role of Assay Type in Determining Free 25-Hydroxyvitamin D Levels in Diverse Populations
Authors: Carrie M Nielson, Kerry S Jones, Roger Bouillon, Rene F Chun, Jon Jacobs, Ying Wang, Martin Hewison, John S Adams, Christine M Swanson, Christine G Lee, Dirk Vanderschueren, Steven Pauwels, Ann Prentice, Richard D Smith, Tujin Shi, Yuqian Gao, Joseph M Zmuda, Jodi Lapidus, Jane A Cauley, Inez Schoenmakers, Eric S Orwoll
Journal: New England Journal of Medicine (2016)

The choice of a vitamin D–binding protein assay is key in calculating free 25-hydroxyvitamin D levels. The results of this analysis support the use of total 25-hydroxyvitamin D as a marker of vitamin D status, regardless of race or GC genotype.
Hospital trusts will have to cut activity when integration fund comes into effect, meeting is told
Authors: N. Hawkes
Journal: BMJ (2013)

The financial deficits facing many trusts will prove “unsustainable” unless the picture improves sharply in the second half of the financial year, said the chief executive of the Trust Development Authority, David Flory.

He told a meeting on 10 December at the health think tank the King’s Fund that 31 of the 99 non-foundation trusts his organisation was responsible for were currently in deficit.

“We can’t go into next year with that many in deficit,” he said. “We have to deal with it, but not in a rush. We have new commissioners, new relationships to form, and that’s taken some time—more than would have been ideal.

“Inevitably, there has been some risk aversion in the new commissioning …
Experience with Anencephalic Infants as Prospective Organ Donors
Authors: Joyce L. Peabody, Janet R. Emery, Stephen Ashwal
Journal: New England Journal of Medicine (1989)

Recent advances have made organ transplantation in newborns feasible, but the paucity of organs small enough for this age group remains a major limitation. Because anencephalic infants can survive for no more than a few weeks, they have been considered as possible organ donors for other infants. Under current law, however, they cannot be used as donors until their brain-stem activity ceases and the criteria for total brain death are thereby met. If anencephalic infants receive customary care, their solid organs usually undergo irreversible hypoxic injury during the process of dying and become unsuitable for donation by the time of death. We modified the medical care of 12 live-born anencephalic infants for one week to determine whether organ viability could be maintained and whether the criteria of total brain death could be met. Six received intensive care from birth, and six only when signs of imminent death developed. Only two infants met the criteria for total brain death within one week, and no solid organs were procured. Most organs were suitable for transplantation at birth. When intensive care was provided from birth, organ function was maintained; however, brain-stem activity ceased in only one infant within the first week. When intensive care was delayed until death was imminent, most organs were damaged to an extent that made them no longer suitable for transplantation. Our findings suggest that it is usually not feasible, with the restrictions of current law, to procure solid organs for transplantation from anencephalic infants.
FRI0567-HPR Criterion Validation of the Submaximal ÅStrand Bicycle Test to Estimate Aerobic Capacity in People with Rheumatoid Arthritis
Authors: C. Fridén, E. Jansson, T. Österlund, W. Grooten, C.H. Opava, A. Rickenlund, B. Nordgren
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Aerobic capacity tests are important to evaluate exercise programs and to encourage individuals to a physically active lifestyle. Maximum aerobic tests in a laboratory setting are expensive and not always feasible for people with rheumatoid arthritis (RA) (1). Submaximal tests, if proven valid and reliable, could thus be an alternative to maximum tests. The Åstrand submaximal bicycle test has been extensively used in clinic and research in people with RA, but never tested for validity and reliability in this population (2). <h3>Objectives</h3> To test the validity of the Åstrand submaximal test for estimation of aerobic capacity, by exploring the correlation with the measured maximum oxygen uptake (measured VO<sub>2max</sub>) in people with RA. <h3>Methods</h3> Twenty seven subjects (81% female), mean (SD) age 62 (8.1) years, diagnosed with RA since 17.9 (11.7) years, activity limitation according to the Stanford Health Assessment Questionnaire 0.412 (0.42) and Disease Activity Score 28 2.4 (0.42), participated in the study. The subjects performed the Åstrand test and the measured VO<sub>2max</sub> test (Alpha version 4.5, Jaeger, KFA-2028-01) at the same test occasion. According to the Åstrand-nomograms the VO<sub>2max</sub> was estimated using heart rate (HR) measurements from a single stage and adjusted for age or for maximal HR. <h3>Results</h3> The correlation between VO<sub>2max</sub> estimated by the Åstrand test corrected for age and the measured VO<sub>2max</sub> test was r =0.82 (p&lt;0.001) when expressed in l/min and r =0.68 (p&lt;0.001) when expressed in ml kg<sup>–1</sup> min<sup>–1</sup>, No systematic over- or underestimations were present although a majority of cases were underestimated. The correlation between VO<sub>2max</sub> estimated by the Åstrand test corrected for maximum HR and the measured VO<sub>2max</sub> test was r =0.82 (p&lt;0.001) when expressed in l/min and r =0.65 (p&lt;0.001) when expressed in ml kg<sup>–1</sup> min<sup>–1</sup>. No systematic over- or under estimations were present. <h3>Conclusions</h3> The Åstrand test could be considered a valid instrument to estimate VO<sub>2max</sub> in physically active people with RA that are able to perform a submaximal cycle test during six minutes <h3>References</h3> Eurenius E, Brodin N, Opava CH. Clinical applicability of of two tests of aerobic fitness in patients with rheumatoid arthritis. Adv Physiother 2007(9):97-104. Astrand PO, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse rate during sub-maximal work. J Appl Physiol. 1954;7(2):218-21. <h3>Acknowledgements</h3> The Swedish Rheumatism Association, the National Postgraduate School of Health Care Sciences at Karolinska Institutet. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5536
Hemichorea–Hemiballism after Diabetic Ketoacidosis
Authors: Andrew P Duker, Alberto J Espay
Journal: New England Journal of Medicine (2010)

A 37-year-old man with insulin-dependent diabetes who had undergone kidney transplantation 7 years earlier presented with delirium caused by diabetic ketoacidosis. His calculated serum osmolarity peaked at 304 mOsm per liter, and the serum glucose level reached 528 mg per deciliter (29.3 mmol per liter). The initial serum sodium level was 132 mmol per liter, which normalized to 139 mmol per liter over 18 hours. The patient's mental status normalized 2 days after the administration of insulin and intravenous hydration. Three weeks later, he noted that his right arm and right leg were “fidgety,” a symptom that rapidly increased in . . .
247 HIGH LEVELS OF SOLUBLE TNF-ALPHA-RECEPTOR-I ARE ASSOCIATED WITH POOR OUTCOME IN CIRRHOSIS WITH PORTAL HYPERTENSION
Authors: J. Trebicka, A. Krag, S. Gansweid, F. Bendtsen, C.P. Strassburg, S. Möller, T. Sauerbruch, U. Spengler
Journal: Journal of Hepatology (2013)
Allergen Challenge Induces Recruitment of CD49d+ Neutrophils to the Nasal Mucosa of Atopic Individuals
Authors: Jerome Sigua, Becky Buelow, Meribeth Klancnik, Desire Hunter, Erika Buell, Monica Vasudev, Dorothy S. Cheung, Mitchell H. Grayson
Journal: Journal of Allergy and Clinical Immunology (2013)
Abstract 2660: Folate conjugated PLGA silica coreshell nanoparticles for drug delivery
Authors: Aschemeyer Sharraya, Jian Yang, Sergio Sandoval, Jesus Alfaro, Andrew Kummel, William C. Trogler
Journal: Cancer Research (2010)

Abstract Folate conjugated poly(lactic-co-glycolic acid) (PLGA) silica nanoparticles (NP) are being synthesized as drug carriers to cancer cells. The PLGA nanoparticles are synthesized by first combining PLGA and dye in acetonitrile. This mixture is then dropped into an aqueous solution containing lecithin (a lipid) and poly(ethylene glycol) (PEG) to form an emulsion. The acetonitrile is evaporated leaving the nanoparticles in a water suspension. Silicic acid is used to coat the PLGA NP through the sol-gel process assisted by poly-L-lysine to template the growth of the silica shell. This makes a more hydrophilic and easily modified surface. 3-aminopropyltriethoxysilane is used to coat the silica surface with amine groups. Then folic acid is coupled to the amine modified silica surface. The folic acid acts as a targeting agent which recognizes folate receptors on the membrane surface of cancer cells. A fluorescent dye is loaded into the PLGA core to mimic a hydrophobic drug in these initial studies. Then the ability of PLGA silica NP with folate are allowed to undergo endocytosis into the HeLa cells, and the degree of uptake is assessed by fluorescence microscopy. The results are compared to folate PLGA NP as a control. Detailed synthesis of these silica PLGA nanoparticles, their characterization, surface functionalization, and their applications will be presented. This presentation was made possible by NIH grants:5P30CA23100; and 1U54CA132379/1U54CA132384. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2660.
CHANGES IN INTERVENTIONS IN TYPE B ACUTE AORTIC DISSECTION PATIENTS
Authors: Sevan Misirliyan, Santi Trimarchi, Firas F. Mussa, Rossella Fattori, Ali Khoynezhad, Daniel Montgomery, Arturo Evangelista, Marco Di Eusanio, Eva Kline-Rogers, Truls Myrmel, Khaled Abdul-Nour, G. Michael Deeb, Eric Isselbacher, Christoph Nienaber, Kim Eagle, Himanshu Patel
Journal: Journal of the American College of Cardiology (2015)
Tc-99m Nanocolloid and MRI Evaluation of Extramedullary Hematopoiesis in Thalassemia Major
Authors: G Rubini, V Sabato, A D'Addabbo
Journal: Clinical Nuclear Medicine (1998)

Tc-99m nanocolloid bone marrow scintigraphy of a patient with thalassemia major showed a high degree hepatomegaly and active bone marrow throughout the skeleton with elevated radionuclide uptake in the cranium, the pelvis, and the proximal and distal ends of both tibiae. Areas of increased nanocolloid uptake in the right paravertebral and dorsal areas were associated with sites of extramedullary erythropoiesis. MRI identified the two intrathoracic masses in the chest.